Chapter 3: Pharmacodynamics — Module 1: The Receptor Concept, Binding Kinetics and Drug-Receptor Interaction
1. A drug has a Kd of 0.5 nM at its target receptor in a binding assay. In a functional assay measuring receptor-mediated smooth muscle relaxation, the EC50 (the concentration producing 50% of maximum effect) is 0.05 nM -- 10-fold lower than the Kd. Which of the following best explains this discrepancy?
A) The binding assay was performed under non-equilibrium conditions, causing an artifactually high Kd that does not reflect true receptor affinity at physiological equilibrium
B) The drug undergoes local metabolic activation within the tissue to a more potent active metabolite; the functional EC50 reflects the concentration of the active metabolite rather than the parent compound
C) The tissue contains a substantial receptor reserve -- more receptors are present than needed to produce a maximum response; because only a small fraction of receptors needs to be occupied to produce maximum smooth muscle relaxation, EC50 is achieved at a drug concentration far below that required to occupy 50% of receptors (Kd), explaining the 10-fold discrepancy
D) The smooth muscle relaxation assay measures a downstream effector response rather than direct receptor activation, and the signal amplification through second messenger cascades lowers the apparent EC50 below the Kd
E) The Kd reflects the drug's affinity for both active and inactive receptor conformations, while the EC50 reflects affinity only for the active conformation; the drug has 10-fold higher affinity for the active conformation, which is preferentially detected in the functional assay
ANSWER: C
Rationale:
The discrepancy between Kd (binding affinity) and EC50 (functional potency) is the pharmacodynamic signature of receptor reserve. Kd is the drug concentration at which 50% of receptor binding sites are occupied at equilibrium. EC50 is the drug concentration producing 50% of maximum functional response. In a tissue with receptor reserve, maximum functional response is achieved when only a small fraction of total receptors are occupied. If maximum smooth muscle relaxation requires only 5% receptor occupancy, then EC50 -- the concentration producing 50% of maximum relaxation -- is achieved at a concentration far below that needed to occupy 50% of receptors. The ratio EC50/Kd reflects the degree of receptor amplification: an EC50 10-fold lower than Kd indicates that only approximately 10% of receptors need be occupied for maximum response, meaning approximately 90% of receptors are spare. This amplification is tissue-specific and reflects the efficiency of stimulus-response coupling in that tissue.
Option A: Option A is incorrect -- non-equilibrium binding conditions would produce unreliable Kd estimates, but the systematic 10-fold discrepancy in the same tissue is not explained by assay artifact; receptor reserve is the established pharmacological explanation.
Option B: Option B is incorrect -- local metabolic activation would affect the functional assay but not the binding assay performed with the parent compound; the discrepancy between binding and function is the key finding, and metabolic activation would affect both if the metabolite competed at the same receptor.
Option D: Option D is incorrect -- while signal amplification through second messenger cascades does contribute to the relationship between receptor occupancy and functional response, this is the mechanistic basis of receptor reserve, not a separate explanation; the correct framing is receptor reserve, which encompasses signal amplification.
Option E: Option E is incorrect -- the two-state model predicts that agonists with selectivity for the active receptor conformation can produce constitutive activity, but the discrepancy described (Kd vs EC50) is most parsimoniously explained by receptor reserve in the functional tissue, not by differential affinity for receptor conformational states.
2. A competitive antagonist is added to a tissue preparation at a fixed concentration. When the agonist dose-response curve is constructed in the presence of the antagonist, which of the following correctly describes the expected result?
A) The curve shifts leftward (lower EC50) with no change in Emax -- indicating that the antagonist paradoxically sensitizes the receptor to the agonist through allosteric facilitation
B) Emax is reduced without a shift in EC50 -- indicating that the antagonist is blocking a population of receptors irreversibly, eliminating receptor reserve without altering agonist potency at remaining receptors
C) Both EC50 and Emax are reduced proportionally -- indicating a mixed mechanism combining receptor occupancy competition with downstream signal attenuation
D) The curve shifts rightward (higher EC50) with a reduction in Emax -- indicating that the antagonist has both competitive and non-competitive components, consistent with an allosteric mechanism that reduces agonist efficacy
E) The curve shifts rightward (higher EC50) with no change in Emax -- indicating surmountable antagonism; at sufficiently high agonist concentrations, the agonist outcompetes the antagonist for receptor occupancy, restoring maximum response; the degree of rightward shift is quantified by the Schild equation and yields the pA2 value for the antagonist
ANSWER: E
Rationale:
Competitive antagonism at a receptor produces a characteristic and predictable pharmacodynamic signature: parallel rightward shift of the agonist dose-response curve with no reduction in Emax. The mechanism is straightforward -- the competitive antagonist occupies the same orthosteric binding site as the agonist and competes for receptor occupancy according to the law of mass action. At any given antagonist concentration, increasing agonist concentration progressively displaces the antagonist from the receptor, and at sufficiently high agonist concentrations the agonist occupies virtually all receptors and produces maximum response. This means Emax is preserved -- maximum effect is still achievable, just at a higher agonist concentration. The EC50 is increased (potency is reduced) because more agonist is required to achieve 50% of maximum effect in the presence of the competing antagonist. The degree of rightward shift is quantified by the dose ratio (DR) -- the ratio of EC50 in the presence versus absence of antagonist. Schild analysis of dose ratios across multiple antagonist concentrations yields the pA2, which is equal to -log(KB) where KB is the antagonist's equilibrium dissociation constant at the receptor. This makes competitive antagonism pharmacodynamically useful: the antagonist effect is always surmountable by increasing agonist concentration, and quantitative analysis yields precise receptor affinity measurements.
Option A: Option A is incorrect -- a leftward shift with no Emax change would indicate sensitization or positive allosteric modulation, the opposite of antagonism.
Option B: Option B is incorrect -- Emax reduction without EC50 shift is the signature of irreversible (non-competitive) antagonism that eliminates receptor reserve; competitive antagonism does not reduce Emax.
Option C: Option C is incorrect -- proportional reduction in both EC50 and Emax has no established mechanistic basis in simple competitive antagonism; this pattern does not correspond to a standard pharmacodynamic interaction model.
Option D: Option D is incorrect -- rightward shift with Emax reduction indicates non-competitive or insurmountable antagonism; a purely competitive antagonist at equilibrium does not reduce Emax.
3. A patient on therapeutic-dose buprenorphine for opioid use disorder is prescribed oxycodone for acute pain. Despite standard analgesic doses, the oxycodone produces minimal pain relief. Which of the following best explains this pharmacodynamic interaction?
A) Buprenorphine's very high affinity for the mu-opioid receptor and its extremely slow receptor dissociation rate (koff) mean it occupies the majority of available mu-opioid receptors continuously; oxycodone cannot effectively displace buprenorphine despite competing for the same orthosteric site, because buprenorphine's Kd is far lower than oxycodone's; the mu-opioid receptors available for oxycodone binding are insufficient to produce adequate analgesia at standard doses
B) Buprenorphine induces rapid upregulation of mu-opioid receptor gene transcription, increasing receptor density to the point where oxycodone's receptor reserve is so large that standard doses produce only sub-threshold receptor occupancy insufficient for analgesia
C) Buprenorphine selectively downregulates only the mu-opioid receptors that respond to full agonists such as oxycodone, while preserving the partial agonist-sensitive receptor population; oxycodone therefore has no functional receptors available despite normal total receptor density
D) Oxycodone requires metabolic activation to oxymorphone in the liver, and buprenorphine inhibits the CYP2D6-mediated conversion, preventing formation of the active metabolite responsible for oxycodone's analgesic effect
E) Buprenorphine permanently phosphorylates mu-opioid receptors via a GRK (G protein-coupled receptor kinase)-independent mechanism, producing irreversible receptor desensitization that persists throughout the buprenorphine dosing interval and blocks subsequent agonist signaling
ANSWER: A
Rationale:
Buprenorphine is a partial agonist at the mu-opioid receptor with several unusual pharmacokinetic and pharmacodynamic properties that make it clinically problematic when combined with full opioid agonists. Its most pharmacologically distinctive feature is its extremely high receptor affinity -- its Kd at the mu-opioid receptor is in the sub-nanomolar range, far below that of most full opioid agonists including oxycodone, morphine, and fentanyl. Coupled with this high affinity is an unusually slow receptor dissociation rate (small koff), meaning buprenorphine remains bound to mu-opioid receptors for prolonged periods. The consequence is that at therapeutic buprenorphine plasma concentrations, the vast majority of available mu-opioid receptors are continuously occupied by buprenorphine. When oxycodone is administered, it cannot effectively compete for these occupied receptors -- the law of mass action favors buprenorphine retention because of its superior affinity and slow koff. The small fraction of receptors not occupied by buprenorphine is insufficient to produce meaningful analgesia at standard oxycodone doses. This is a clinically important interaction: patients on buprenorphine maintenance therapy who require acute analgesia typically need either very high doses of full agonists (sufficient to overcome buprenorphine's competitive advantage), regional anesthesia, or non-opioid analgesic strategies.
Option B: Option B is incorrect -- buprenorphine does not upregulate mu-opioid receptor density; receptor upregulation would increase, not decrease, oxycodone's analgesic effect.
Option C: Option C is incorrect -- there is no pharmacological mechanism by which buprenorphine selectively downregulates full agonist-sensitive receptors while preserving partial agonist-sensitive populations; all mu-opioid receptors are the same molecular entity.
Option D: Option D is incorrect -- buprenorphine does not inhibit CYP2D6 in a clinically significant way; the interaction is pharmacodynamic (receptor competition), not pharmacokinetic.
Option E: Option E is incorrect -- buprenorphine does not irreversibly phosphorylate mu-opioid receptors; receptor phosphorylation by GRK is an agonist-driven process and is reversible; buprenorphine's long duration of action reflects its slow koff from the receptor, not irreversible receptor modification.
4. In the context of receptor theory, what does it mean to say that a drug's duration of antiplatelet effect is "governed by receptor turnover rather than by plasma drug elimination"?
A) It means the drug is eliminated slowly from plasma, with a pharmacokinetic half-life that matches the duration of antiplatelet effect, so drug concentration in plasma remains sufficient for receptor occupancy throughout the therapeutic window
B) It means the drug accumulates irreversibly in platelet phospholipid membranes and continues to inhibit platelet aggregation through membrane-based mechanisms even after the drug is no longer detectable at the receptor protein
C) It means the rate-limiting step for recovery is the upregulation of compensatory thromboxane synthesis pathways in response to drug-induced inhibition, which takes 7-10 days to overcome the pharmacodynamic effect
D) It means the drug has covalently modified its target such that pharmacological effect persists as long as the modified receptor (or cell) survives; recovery requires synthesis of new, unmodified receptor protein or generation of new cells; for aspirin and platelets, recovery is complete only when new aspirin-naive platelets replace those whose COX-1 was acetylated -- a process taking 7-10 days reflecting platelet lifespan, not aspirin pharmacokinetics
E) It means drug receptor dissociation is so slow that the calculated koff gives a binding half-life of 7-10 days, matching the duration of antiplatelet effect through kinetic rather than covalent mechanisms
ANSWER: D
Rationale:
When pharmacological effect duration is governed by receptor turnover rather than drug elimination, the drug has formed a covalent bond with its target that cannot be reversed by pharmacokinetic processes. Aspirin is the prototype: it acetylates COX-1 in platelets irreversibly. Once aspirin is cleared from plasma (plasma half-life approximately 15-20 minutes for the parent compound), there is no aspirin left to block new COX-1 -- but the existing COX-1 in platelets is already permanently inactivated. Recovery of platelet COX-1 activity requires synthesis of new COX-1 protein. Platelets cannot synthesize new proteins because they are anucleate -- they have no nucleus to drive transcription. Therefore COX-1 recovery in platelets requires generation of new aspirin-naive platelets from megakaryocytes. The bone marrow produces approximately 10-15% of the circulating platelet mass per day, so complete replacement of the platelet pool takes approximately 7-10 days. This is why the duration of aspirin's antiplatelet effect (7-10 days) reflects platelet lifespan, not aspirin's plasma pharmacokinetics. Clinically, this explains why aspirin must be stopped 7-10 days before surgery if platelet function needs to be restored, and why platelet transfusion is needed for emergency reversal.
Option A: Option A is incorrect -- this describes pharmacokinetic-governed duration, the opposite of the concept being tested; aspirin plasma levels are undetectable within hours.
Option B: Option B is incorrect -- aspirin's persistence in platelet membranes is not the mechanism; the covalent COX-1 acetylation, not membrane accumulation, governs duration.
Option C: Option C is incorrect -- thromboxane synthesis recovery reflects the same platelet turnover timeline, not upregulation of compensatory pathways; the mechanism is receptor resynthesis (new platelets), not pathway compensation.
Option E: Option E is incorrect -- aspirin's effect is governed by covalent modification, not by slow non-covalent dissociation; a koff producing a 7-10 day binding half-life would require an extraordinarily tight non-covalent interaction that has not been described for aspirin.
5. Why does a radioligand binding assay fail to identify whether a compound is an agonist, a neutral antagonist, or an inverse agonist at a G protein-coupled receptor (GPCR)?
A) Binding assays cannot achieve equilibrium conditions for all three types of ligands simultaneously because agonists, neutral antagonists, and inverse agonists have different kon and koff values that prevent simultaneous equilibration in a single assay format
B) All three compound classes can bind the receptor with high affinity -- binding assays measure receptor occupancy (the physical drug-receptor interaction) but cannot detect whether receptor activation, no activation, or inverse activation occurs upon binding; discrimination between agonist, neutral antagonist, and inverse agonist requires a functional assay that measures the downstream consequence of receptor occupancy
C) Radioligand competition assays use saturating concentrations of the radioligand that sterically prevent agonist-induced receptor conformational changes, artifactually converting all ligands to apparent neutral antagonists in the binding assay format
D) Inverse agonists and neutral antagonists have identical Kd values by definition because they both bind without producing receptor activation; binding assays can distinguish these two from agonists but cannot distinguish between the two non-activating classes
E) Binding assays are performed in cell-free membrane preparations that lack the G proteins and second messenger systems required to observe agonist-induced effects; adding G proteins to the assay system would allow discrimination of all three ligand classes based on their differential GTP sensitivity
ANSWER: B
Rationale:
Radioligand binding assays measure the physical interaction between a drug and its receptor -- they detect binding affinity (Kd) and receptor density (Bmax) but provide no information about what happens after binding. A full agonist, a neutral antagonist, and an inverse agonist can all bind the same receptor with high affinity and similar Kd values. From the perspective of the receptor binding site, occupancy is occupancy -- the receptor does not report whether it is being activated, silenced, or held neutral. What differs between the three ligand classes is the downstream consequence of binding: agonists stabilize the active receptor conformation and activate G protein signaling; neutral antagonists bind without stabilizing either active or inactive conformations (or stabilize both equally); inverse agonists preferentially stabilize the inactive receptor conformation and reduce constitutive (basal) signaling below the unliganded receptor baseline. None of these consequences is detectable by measuring radioligand displacement. Discrimination requires functional assays -- measuring cAMP accumulation, GTP hydrolysis (GTPase activity), second messenger production, or reporter gene expression -- in which agonists increase signaling, neutral antagonists produce no change, and inverse agonists reduce basal signaling.
Option A: Option A is incorrect -- equilibrium can be achieved for all ligand classes in a binding assay; the failure to distinguish them is not a kinetic limitation but a fundamental limitation of what binding measures.
Option C: Option C is incorrect -- saturating radioligand concentrations do not sterically prevent receptor conformational changes; radioligands compete for binding but do not lock receptor conformation; competition binding assays can use sub-saturating radioligand conditions.
Option D: Option D is incorrect -- inverse agonists and neutral antagonists do not have identical Kd values by definition; their Kd values at any given receptor are determined by their individual chemical structures and binding interactions; a binding assay cannot distinguish them because both appear simply as receptor occupants without signaling consequences.
Option E: Option E is incorrect -- while GTP-sensitive binding assays (using non-hydrolyzable GTP analogs such as GppNHp) can distinguish agonists from non-agonists in some receptor systems, this is a specialized variant; the standard binding assay fundamentally cannot distinguish agonism from antagonism.
ANSWER KEY: Q1=C Q2=E Q3=A Q4=D Q5=B
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.